Award
National Cancer Institute 5R01CA258994-05
PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?
Recipient
Indiana University Indianapolis, Department of Urology
Award Amount
$383,683.00
Ceiling
$383,683.00
Awarded
February 02, 2026
Identifier
5R01CA258994-05
This award funds a Phase II clinical trial to evaluate PSMA-PET imaging for guiding prostate cancer surgery to improve surgical outcomes and patient quality of life by reducing nerve damage.
Description
The project investigates the use of the radiopharmaceutical 68Ga-P16-093, targeting prostate specific membrane antigen (PSMA), to guide prostate cancer surgery. The Phase II clinical trial aims to assess the accuracy of PSMA-PET in detecting extraprostatic extension of prostate cancer, compare it with mpMRI, and evaluate how imaging influences surgical planning and patient quality of life. The study involves a randomized controlled trial with one group receiving standard care and the other receiving additional PSMA-PET imaging. Outcomes include surgical modifications, preservation of nerves and muscles, and post-surgical quality of life improvements.